11960
Quantification Of Benefit-risk In Amyloid-targeting Therapies For Cognitively Unimpaired Alzheimer's Disease
Oralee J Varnado, Matthew Quaife, Jaein Seo, Antje Tockhorn-Heidenreich, Nalin Payakachat, Yasmijn Slaghekke, Álvaro Alberto Gutiérrez-Vargas, J. Scott Andrews, Niklas Mattsson-Carlgren
Eli Lilly and Company, Indianapolis, IN, USA, PPD Evidera Patient-Centered Research, Thermo Fisher Scientific, London, UK, PPD Evidera Patient-Centered Research, Thermo Fisher Scientific, Waltham, MA, USA, Clin...
Poster Presenter: Oralee Varnado